We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 606

FDA brings successful enforcement actions against dietary supplement makers
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The U.S. Food and Drug Administration (FDA) has obtained a permanent injunction against Truman Berst who sells, as Alternative Health & Herbs Remedies, herbs and dietary supplements with disease-treatment claims


Neumedicines receives $8.3 million from BARDA for radiation sickness drug
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Pasadena-based Neumedicines Inc. has reportedly received $8.3 million from the Biomedical Advanced Research & Development Authority (BARDA) of the U


False-marking plaintiff challenges retroactive application of AIA standing requirement
  • Shook Hardy & Bacon LLP
  • USA
  • November 17 2011

A Benjamin N. Cardozo School of Law-affiliated non-profit legal services organization, known as the Public Patent Foundation, has filed a pleading in its false-marking lawsuit against the company that makes Tylenol products, challenging the constitutionality of a retroactive America Invents Act (AIA) provision that would divest the non-profit of standing


Physician explores future of whole genome sequencing
  • Shook Hardy & Bacon LLP
  • USA
  • June 16 2011

“The iconic $1,000 genome is very close to a realityat least in terms of reagent costs,” writes Eleanor Herriman, director of G2 Research and Analysis with Kennedy Information Inc., in a June 3, 2011, article for BNA’s Life Sciences Law & Industry Report


Viropharma to acquire Swedish pharma in deal worth up to $164.6 million
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline


Campaign seeks to reinforce Hudson Valley as a biotech industry hub
  • Shook Hardy & Bacon LLP
  • USA
  • November 4 2010

Senator Kirsten Gillibrand (D-N.Y.) and business leaders have reportedly unveiled a “NY BioHud Valley” campaign that highlights the state’s Hudson Valley as a “burgeoning epicenter of the biotech industry.”


Quebec establishes new venture capital fund to invest in biotech research
  • Shook Hardy & Bacon LLP
  • Canada
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research


Agilent Technologies acquires BIOCIUS Life Sciences
  • Shook Hardy & Bacon LLP
  • USA
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions


NIH to fund research centers targeting genetic causes of CHD
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

The National Institutes of Health (NIH) will award more than $2 million in fiscal year 2015 to research centers that will join the Pediatric Cardiac


County pharmaceutical disposal law at issue before Ninth Circuit
  • Shook Hardy & Bacon LLP
  • USA
  • July 17 2014

The Ninth Circuit Court of Appeals has heard oral argument in an appeal challenging an Alameda County, California law that requires pharmaceutical